We recently compiled a list of the 10 Firms Buck Market Bloodbath on Monday. In this article, we are going to take a look at ...

Wedbush raised the firm’s price target on Protagonist Therapeutics (PTGX) to $70 from $58 and keeps an Outperform rating on the shares.Optimize ...

The joint development project of Protagonist Therapeutics and Johnson & Johnson (NYSE:JNJ) produced Icotrokinra as their ...

Truist raised the firm’s price target on Protagonist Therapeutics (PTGX) to $76 from $60 and keeps a Buy rating on the shares. The firm cites ...

HC Wainwright reissued their buy rating on shares of Protagonist Therapeutics (NASDAQ:PTGX – Free Report) in a research note ...

On Monday, Protagonist Therapeutics, Inc. PTGX announced topline results from ANTHEM-UC Phase 2b study of icotrokinra ...

Protagonist Therapeutics, Inc. (NASDAQ:PTGX – Get Free Report) has been assigned an average recommendation of “Buy” from the nine research firms that are presently covering the stock, Ratings reports.

Protagonist Therapeutics (NASDAQ:PTGX) and Takeda (NYSE:TAK) said on Monday that its late-stage study of rusfertide for the ...

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) and Takeda Pharmaceutical Co Ltd (NYSE:TAK) released topline results for the ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...